Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody

Journal of Lipid Research

Volumn 56, Issue 11, 2015, Pages 2124-2132

  Schroeder, Krista M ^a   Beyer, Thomas P ^a   Hansen, Ryan J ^a   Han, Bomie ^a   Pickard, Richard T ^a   Wroblewski, Victor J ^a   Kowala, Mark C ^a   Eacho, Patrick I ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Drug therapy; Dyslipidemias; Low density lipoprotein metabolism; Mass spectrometry; Pharmacokinetics; Pharmacology; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ADENOVIRUS VECTOR; EPITOPE; FURIN; IMMUNOGLOBULIN G4; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LY 3015014; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SECRETORY PROTEIN; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; LY3015014; PCSK9 PROTEIN, MOUSE; PROPROTEIN CONVERTASE 9; PROTEIN BINDING; SERINE PROTEINASE;

ANTIBODY PRODUCTION; ARTICLE; CLEARANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG EFFICACY; DRUG PROTEIN BINDING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SINGLE DRUG DOSE; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CHEMISTRY; DRUG STABILITY; HALF LIFE TIME; HYPERCHOLESTEROLEMIA; IMMUNOLOGY; PRECLINICAL STUDY; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DRUG EVALUATION, PRECLINICAL; DRUG STABILITY; FURIN; HALF-LIFE; HUMANS; HYPERCHOLESTEROLEMIA; MACACA FASCICULARIS; MALE; MICE, INBRED BALB C; MICE, INBRED C57BL; PROPROTEIN CONVERTASE 9; PROPROTEIN CONVERTASES; PROTEIN BINDING; PROTEOLYSIS; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84948807804     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M061903     Document Type: Article

References (38)

1. Horton, J. D., J. C. Cohen, and H. H. Hobbs. 2009. PCSK9: A convertase that coordinates LDL catabolism. J. Lipid Res. 50 ( Suppl. ): S172 - S177.
2. Peterson, A. S., L. G. Fong, and S. G. Young. 2008. PCSK9 function and physiology. J. Lipid Res. 49 : 1595 - 1599.
3. McNutt, M. C., T. A. Lagace, and J. D. Horton. 2007. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J. Biol. Chem. 282 : 20799 - 20803.
4. Maxwell, K. N., and J. L. Breslow. 2004. Adenoviral-mediated expression of PCSK9 in mice results in a low- density lipoprotein receptor knockout phenotype. Proc. Natl. Acad. Sci. USA. 101 : 7100 - 7105.
5. Rashid, S., D. E. Curtis, R. Garuti, N. N. Anderson, Y. Bashmakov, Y. K. Ho, R. E. Hammer, Y. Moon, and J. D. Horton. 2005. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking PCSK9. Proc. Natl. Acad. Sci. USA. 102 : 5374 - 5379.
6. Maxwell, K. N., E. A. Fisher, and J. L. Breslow. 2005. Overexpression of PCSK9 accelerates the degradation of the LDLR in a postendoplasmic reticulum compartment. Proc. Natl. Acad. Sci. USA. 102 : 2069 - 2074.
7. Abifadel, M., M. Varret, J. Rabès, D. Allard, K. Ouguerram, M. Devillers, C. Cruaud, S. Benjannet, L. Wickham, D. Erlich, et al. 2003. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat. Genet. 34 : 154 - 156.
8. Cunningham, D., D. E. Danley, K. F. Geoghegan, M. C. Griffor, J. L. Hawkins, T. A. Subashi, A. H. Varghese, M. J. Ammirati, J. S. Culp, L. R. Hoth, et al. 2007. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat. Struct. Mol. Biol. 14 : 413 - 419.
9. Cohen, J., A. Pertsemlidis, I. K. Kotowski, R. Graham, C. K. Garcia, and H. H. Hobbs. 2005. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37 : 161 - 165.
10. Kotowski, I. K., A. Pertsemlidis, A. Luke, R. S. Cooper, G. L. Vega, J. C. Cohen, and H. H. Hobbs. 2006. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78 : 410 - 422.
11. Cohen, J. C., E. Boerwinkle, T. H. Mosley, Jr., and H. H. Hobbs. 2006. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 : 1264 - 1272.
12. Luo, Y., L. Warren, D. Xia, H. Jensen, T. Sand, S. Petras, W. Qin, K. S. Miller, and J. Hawkins. 2009. Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice. J. Lipid Res. 50 : 1581 - 1588.
13. Zaid, A., A. Roubtsova, R. Essalmani, J. Marcinkiewicz, A. Chamberland, J. Hamelin, M. Tremblay, H. Jacques, W. Jin, J. Davignon, et al. 2008. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specifi c low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 48 : 646 - 654.
14. Grefhorst, A., M. C. McNutt, T. A. Lagace, and J. D. Horton. 2008. Plasma PCSK9 preferentially reduces liver LDL receptors in mice. J. Lipid Res. 49 : 1303 - 1311.
15. Benjannet, S., D. Rhainds, R. Essalmani, J. Mayne, L. Wickham, W. Jin, M. Asselin, J. Hamelin, M. Varret, D. Allard, et al. 2004. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J. Biol. Chem. 279 : 48865 - 48875.
16. Benjannet, S., D. Rhainds, J. Hamelin, N. Nassoury, and N. G. Seidah. 2006. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post- Translational modifi cations. J. Biol. Chem. 281 : 30561 - 30572.
17. Han, B., P. I. Eacho, M. D. Knierman, J. S. Troutt, R. J. Konrad, X. Yu, and K. M. Schroeder. 2014. Isolation and characterization of the circulating truncated form of PCSK9. J. Lipid Res. 55 : 1505 - 1514.
18. Essalmani, R., D. Susan-Resiga, A. Chamberland, M. Abifadel, J. W. Creemers, C. Boileau, N. G. Seidah, and A. Prat. 2011. In vivo evidence that furin from hepatocytes inactivates PCSK9. J. Biol. Chem. 286 : 4257 - 4263.
19. Lipari, M. T., W. Li, P. Moran, M. Kong-Beltran, T. Sai, J. Lai, S. J. Lin, G. Kolumam, J. Zavala-Solorio, A. Izrael-Tomasevic, et al. 2012. Furin-cleaved proprotein convertase subtilisin/kexin type 9 (PCSK9) is active and modulates LDL receptor and serum cholesterol levels. J. Biol. Chem. 287 : 43482 - 43491.
20. Bottomley, M. J., A. Cirillo, L. Orsatti, L. Ruggeri, T. S. Fisher, J. C. Santoro, R. T. Cummings, R. M. Cubbon, P. Lo Surdo, A. Calzetta, et al. 2009. Structural and biochemical characterization of the wild type PCSK9-EGF(AB) complex and natural familial hypercholesterolemia mutants. J. Biol. Chem. 284 : 1313 - 1323.
21. Piper, D. E., S. Jackson, Q. Liu, W. G. Romanow, S. Shetterly, S. T. Thibault, B. Shan, and N. C. Walker. 2007. The crystal structure of PCSK9: A regulator of plasma LDL-cholesterol. Structure. 15 : 545 - 552.
22. Kwon, H. J., T. A. Lagace, M. C. McNutt, J. D. Horton, and J. Deisenhofer. 2008. Molecular basis for LDL receptor recognition by PCSK9. Proc. Natl. Acad. Sci. USA. 105 : 1820 - 1825.
23. Roth, E. M., J. M. McKenney, C. Hanotin, G. Asset, and E. A. Stein. 2012. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N. Engl. J. Med. 367 : 1891 - 1900.
24. Raal, F., R. Scott, R. Somaratne, I. Bridges, G. Li, S. Wasserman, and E. Stein. 2012. Low-density lipoprotein cholesterol - lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: The reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation. 126 : 2408 - 2417.
25. Ni, Y. G., J. H. Condra, L. Orsatti, X. Shen, S. Di Marco, S. Pandit, M. J. Bottomley, L. Ruggeri, R. T. Cummings, R. M. Cubbon, et al. 2010. A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake. J. Biol. Chem. 285 : 12882 - 12891.
26. Schiele, F., J. Park, N. Redemann, G. Luippold, and H. Nar. 2014. An antibody against the C-terminal domain of PCSK9 lowers LDL cholesterol levels in vivo. J. Mol. Biol. 426 : 843 - 852.
27. Davies, J., R. J. Darling, and B. Allen. Antibodies to PCSK9 and uses thereof. United States patent US 20130071405 A1. 2013 Mar 21.
28. Sleeman, M., J. H. Martin, T. T. Huang, and D. MacDonald. High affi nity human antibodies to PCSK9. United States patent US20100166768 A1. 2010 Jul 1.
29. Jackson, S., N. Walker, D. Piper, B. Shan, W. Shen, J. Chan, C. King, R. Ketchem, C. Mehlin, and T. Carabeo. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9). United States patent US20090326202 A1. 2009 Dec 31.
30. Kieft, K. A., T. M. Bocan, and B. R. Krause. 1991. Rapid on-line determination of cholesterol distribution among plasma lipoproteins after high-performance gel fi ltration chromatography. J. Lipid Res. 32 : 859 - 866.
31. Zhang, L., T. McCabe, J. H. Condra, Y. G. Ni, L. B. Peterson, W. Wang, A. M. Strack, F. Wang, S. Pandit, H. Hammond, et al. 2012. An anti- PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int. J. Biol. Sci. 8 : 310 - 327.
32. Liang, H., Y. Abdiche, R. Chaparro, B. Gomes, J. Hawkins, J. Pons, X. Qiu, P. Strop, and Y. Wang. PCSK9 antagonists. United States patent US2010068199 A1. 2010 Mar 18.
33. Chaparro-Riggers, J., H. Liang, R. M. DeVay, L. Bai, J. E. Sutton, W. Chen, T. Geng, K. Lindquist, M. G. Casas, L. M. Boustany, et al. 2012. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J. Biol. Chem. 287 : 11090 - 11097.
34. DeVay, R. M., D. L. Shelton, and H. Liang. 2013. Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) traffi cking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2). J. Biol. Chem. 288 : 10805 - 10818.
35. DeVay, R. M., L. Yamamoto, D. L. Shelton, and H. Liang. 2015. Common proprotein convertase subtilisin/kexin type 9 (PCSK9) epitopes mediate multiple routes for internalization and function. PLoS One. 10 : e0125127.
36. Tuli, A., M. Sharma, H. L. Capek, N. Naslavsky, S. Caplan, and J. C. Solheim. 2009. Mechanism for amyloid precursor-like protein 2 enhancement of major histocompatibility complex class I molecule degradation. J. Biol. Chem. 284 : 34296 - 34307.
37. Butkinaree, C., M. Canuel, R. Essalmani, S. Poirier, S. Benjannet, M. C. Asselin, A. Roubtsova, J. Hamelin, J. Marcinkiewicz, A. Chamberland, et al. 2015. Amyloid precursor-like protein 2 and sortilin do not regulate the PCSK9 convertase-mediated low density lipoprotein receptor degradation but interact with each other. J. Biol. Chem. 290 : 18609 - 18620.
38. Igawa, T., S. Ishii, T. Tachibana, A. Maeda, Y. Higuchi, S. Shimaoka, C. Moriyama, T. Watanabe, R. Takubo, Y. Doi, et al. 2010. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat. Biotechnol. 28 : 1203 - 1207.